Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

: Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, Deep-Soboslay A, Innis RB, Kleinman JE

Publisher: ELSEVIER SCIENCE BV

: 2012

: Schizophrenia Research

: SCHIZOPHRENIA RESEARCH

: SCHIZOPHR RES

: 141

: 2-3

: 185

: 188

: 4

: 0920-9964

DOI: https://doi.org/10.1016/j.schres.2012.07.021

This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n = 47) compared to controls (n = 43). The CB1 receptor inverse agonist radioligand [H-3]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [H-3]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [F-18]FMPEP-d(2) (80% statistical power, p<0.05). Published by Elsevier B.V.